Pyxis Oncology (NASDAQ:PYXS) Announces Earnings Results

Pyxis Oncology (NASDAQ:PYXS) announced its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Price Performance

PYXS traded down $0.05 on Thursday, reaching $1.61. The company had a trading volume of 1,149,574 shares, compared to its average volume of 834,470. The stock has a 50-day moving average price of $2.54 and a 200-day moving average price of $2.16. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55.

Analyst Upgrades and Downgrades

PYXS has been the topic of several recent research reports. Wedbush increased their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $5.00 target price on Pyxis Oncology in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pyxis Oncology in a research note on Friday, September 25th. HC Wainwright increased their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Wells Fargo & Company upped their price target on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.57.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.